The Emerging Role of Circulating Tumor DNA: Will Tissue Become Obsolete?

2021 ◽  
Keyword(s):  
Circulating Tumor Dna ◽  
Tumor Dna

scholarly journals Liquid biopsy in NSCLC: a new challenge in radiation therapy

2021 ◽  
Author(s):  
Annarita Perillo ◽  
Mohamed Vincenzo Agbaje Olufemi ◽  
Jacopo De Robbio ◽  
Rossella Margherita Mancuso ◽  
Anna Roscigno ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Liquid Biopsy ◽  
Residual Disease ◽  
Biological Fluids ◽  
Circulating Tumor Dna ◽  
Minimum Residual ◽  
Nsclc Patients ◽  
Choice Of Therapy ◽  
Tumor Dna

Lung cancer is the most common cancer and the leading cause of cancer mortality worldwide. To date, tissue biopsy has been the gold standard for the diagnosis and the identification of specific molecular mutations, to guide choice of therapy. However, this procedure has several limitations. Liquid biopsy could represent a solution to the intrinsic limits of traditional biopsy. It can detect cancer markers such as circulating tumor DNA or RNA (ctDNA, ctRNA), and circulating tumor cells, in plasma, serum or other biological fluids. This procedure is minimally invasive, reproducible and can be used repeatedly. The main clinical applications of liquid biopsy in non-small cell lung cancer (NSCLC) patients are the early diagnosis, stratification of the risk of relapse, identification of mutations to guide application of targeted therapy and the evaluation of the minimum residual disease. In this review, the current role of liquid biopsy and associated markers in the management of NSCLC patients was analyzed, with emphasis on ctDNA and CTCs, and radiotherapy.

scholarly journals Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC

2020 ◽  
Author(s):  
Julia Roeper ◽  
Sylke Kurz ◽  
Christian Grohé ◽  
Frank Griesinger
Keyword(s):  
Treatment Duration ◽  
Kinase Inhibitors ◽  
Circulating Tumor Dna ◽  
Real World Data ◽  
Patient Attrition ◽  
Egfr Tki ◽  
Tumor Dna ◽  
Egfr Tkis ◽  
Optimal Treatment Strategy

Clinical trial and real-world data in non-small-cell lung cancer indicate that 10–60% of patients that progressed on first- or second-generation EGFR-targeting tyrosine kinase inhibitors (TKI) do not receive systemic second-line therapy. In our article, we discuss efficacy, safety and treatment duration with different EGFR-TKIs and stress the need for delivery of the most efficacious therapy in the first-line. We also provide our perspective on analysis of circulating tumor DNA and the role of EGFR-TKI in combined therapies. Finally, we review new therapeutic options to overcome resistance to EGFR-TKI. We believe that overall treatment duration and access to different medications in subsequent lines of therapy should be considered when planning the optimal treatment strategy.

scholarly journals The Role Of Circulating Tumor DNA In Therapeutic Resistance

2019 ◽  
Vol Volume 12 ◽  
pp. 9459-9471 ◽  
Author(s):  
Chenxin Xu ◽  
Haixia Cao ◽  
Chen Shi ◽  
Jifeng Feng
Keyword(s):  
Circulating Tumor Dna ◽  
Therapeutic Resistance ◽  
Tumor Dna

scholarly journals Recent Advances in Device Engineering and Computational Analysis for Characterization of Cell-Released Cancer Biomarkers

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 288
Author(s):  
Hesam Abouali ◽  
Seied Ali Hosseini ◽  
Emma Purcell ◽  
Sunitha Nagrath ◽  
Mahla Poudineh
Keyword(s):  
Cancer Progression ◽  
Computational Analysis ◽  
Cancer Biomarkers ◽  
Circulating Tumor Dna ◽  
Treatment Monitoring ◽  
The Subject ◽  
In Silico Models ◽  
Tumor Dna

During cancer progression, tumors shed different biomarkers into the bloodstream, including circulating tumor cells (CTCs), extracellular vesicles (EVs), circulating cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA). The analysis of these biomarkers in the blood, known as ‘liquid biopsy’ (LB), is a promising approach for early cancer detection and treatment monitoring, and more recently, as a means for cancer therapy. Previous reviews have discussed the role of CTCs and ctDNA in cancer progression; however, ctDNA and EVs are rapidly evolving with technological advancements and computational analysis and are the subject of enormous recent studies in cancer biomarkers. In this review, first, we introduce these cell-released cancer biomarkers and briefly discuss their clinical significance in cancer diagnosis and treatment monitoring. Second, we present conventional and novel approaches for the isolation, profiling, and characterization of these markers. We then investigate the mathematical and in silico models that are developed to investigate the function of ctDNA and EVs in cancer progression. We convey our views on what is needed to pave the way to translate the emerging technologies and models into the clinic and make the case that optimized next-generation techniques and models are needed to precisely evaluate the clinical relevance of these LB markers.

Sign in / Sign up

Export Citation Format

Share Document